Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Exclusion Criteria

• •History of anaphylactic or other severe hypersensitivity/infusion reactions to ADCs, monoclonal antibodies (mAbs) and/or their excipients such that the patient in unable to tolerate immunoglobulin/monoclonal antibody administration
• •Any prior history of treatment with maytansine (DM1 or DM4)-based ADC
• •Known intolerance to a maytansinoid
• •Patients with any active or chronic corneal disorders
• •Patients who have any other condition that precludes monitoring of the retina or fundus
• •Impaired cardiac function or clinically significant cardiac disease
• •Known history of Human Immunodeficiency Virus (HIV) infection
• •Active HBV or HCV infection. Patients whose disease is controlled under antiviral therapy should not be excluded. Patients who are anti-HBcAb positive should be HBsAg negative and HBV-DNA negative to be eligible